贝伐单克隆抗体对二乙基亚硝胺诱导的原发性肝癌大鼠的防治作用及其对肝癌组织VEGF表达的影响

doi:10.3969/j.issn.1672-5069.2017.05.014

摘要/Abstract

摘要： 目的研究抗血管内皮生长因子（VEGF）单克隆抗体对二乙基亚硝胺（DEN）所致原发性肝癌大鼠的干预作用及其对肝组织VEGF表达的影响。方法将30只SD 大鼠随机分为正常组、模型组和药物干预组。采用联合应用四氯化碳和DEN法制备原发性肝癌模型，并给予抗VEGF单克隆抗体腹腔注射干预，在正常组和模型组则给予等体积生理盐水注射。连续干预12 w。实验结束，取血和肝组织行相关检查，采用免疫组化法检测肝组织VEGF表达。结果药物干预组大鼠肝质量、肝表面癌结节数，癌变率和肝脏指数分别为（17.51±2.53）g、（6.86±0.82）个、30%和（4.10±0.79），均明显低于模型组的【（23.71±3.01）、（21.91±2.75）、100.0%和（5.90±1.01），P<0.05】；与模型组比，药物干预组大鼠血清AST、ALT和TBIL水平分别为（101.58±19.83） IU/L、（241.52±36.58） IU/L和（62.93±3.03） μmol/L，均明显低于模型组（P<0.05）；病理学检查结果显示，与模型组比，药物干预组动物肝组织损伤明显减轻；免疫组化检测结果则显示，模型组、正常组和药物干预组VEGF相对表达量分别为（35.21±6.92）、（1.00±0.00）和（11.53±3.81），差异显著（P＜0.05）。结论抗VEGF单克隆抗体对DEN诱导的原发性肝癌大鼠具有较好的抑瘤作用，而这种作用可能与其抑制了肝组织VEGF表达有关。

关键词: 原发性肝癌, 二乙基亚硝胺, 抗血管内皮生长因子单克隆抗体, 大鼠

Abstract: Objective To investigate the inhibition of tumor growth and vascular endothelial growth factor （VEGF） expression of bevacizumab in rats with diethylnitrosamine-induced hepatic neoplasma. Methods 30 SD rats were randomly divided into control，model and bevacizumab-intervened groups. The combination of tetrachloromethane and diethylnitrosamine（DEN） were used to establish liver cancer in rats. The bevacizumab or saline was given intraperitoneally for 12 weeks. The sera and liver tissues were obtained. The liver weights， surface carcinoma nodule numbers，canceration rates and liver index were detected. The VEGF expression was stained immunohistochemically. Results The liver weights，surface carcinoma nodule numbers，canceration rates and liver index were（17.51±2.53） g，（6.86±0.82），30% and（4.10±0.79） in the bevacizumab-intervened group， significantly lower than those in the model group[（23.71±3.01），（21.91±2.75），100.0% and（5.90±1.01）， respectively，P<0.05]；serum AST，ALT and TBIL levels were（101.58±19.83） IU/L，（241.52±36.58） IU/L and （62.93±3.03） μmol/L in the bevacizumab-intervened group，significantly lower than those in the model group（P<0.05）；Liver pathological examination showed that the liver injures，canceration and VEGF expression were alleviated in the bevacizumab-intervened group. Conclusions The application of Bevacizumab has a good inhibitory effect on DEN-induced canceration in rats，which warrants further study.

Key words: Hepatoma, Diethylnitrosamine, Bevacizumab, Rats

张锋利，田华，吴洁琼. 贝伐单克隆抗体对二乙基亚硝胺诱导的原发性肝癌大鼠的防治作用及其对肝癌组织VEGF表达的影响[J]. 实用肝脏病杂志, 2017, 20(5): 563-566.

Zhang Fengli，Tian Hua，Wu Jieqiong.. Inhibition of tumor growth and vascular endothelial growth factor expression of bevacizumab in rats with diethylnitrosamine-induced hepatic neoplasma[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2017, 20(5): 563-566.

参考文献

[1] Liu W，Liu Q，Huang Q，et al. Time trend analysis of primary liver cancer incidence in Sihui county of Guangdong Province， China （1987-2011）. BMC Cancer，2016，16（1）:365-372.
[2] Shibata M，Minami S，Oe S，et al. Recognition of infection，status of outpatient treatment，and treatment history before carcinogenesis in patients with viral hepatitis-associated liver cancer. Nihon Shokakibyo Gakkai Zasshi，2016，113（10）:1734-1742.
[3] 侯帅，樊琳琳，戴光荣. 非手术治疗原发性肝癌研究进展. 实用肝脏病杂志，2016，19（2）:249-252.
[4] Aleksandrova K，Bamia C，Drogan D，et al. The association of coffee intake with liver cancer risk is mediated by biomarkers of inflammation and hepatocellular injury:data from the European prospective investigation into cancer and nutrition. Am J Clin Nutr，2015，102（6）:1498-1508.
[5] Goel HL，Mercurio AM. VEGF targets the tumour cell. Nat Rev Cancer，2013，13（12）:871-882.
[6] Jais A，Solas M，Backes H，et al. Myeloid-cell-derived VEGF maintains brain glucose uptake and limits cognitive impairment in obesity. Cell，2016，165（4）:882-895.
[7] Montero AJ，Escobar M，Lopes G，et al. Bevacizumab in the treatment of metastatic breast cancer:friend or foe Curr Oncol Rep，2012，14（1）:1-11.
[8] 陈万灵，欧阳学农. 新药抗VEGF单克隆抗体的临床应用进展. 中国肿瘤，2010，19（8）:534-539.
[9] 孙敬方. 动物实验方法学. 人民卫生出版社，2001:198-201.
[10] 周剑寅，尹震宇，王生育. 熊胆对二乙基亚硝胺诱发大鼠肝癌的影响. 药学学报，2012，47（11）:1483-1488.
[11] Kudo M，Kitano M，Sakurai T，et al. General rules for the clinical and pathological study of primary liver cancer，nationwide follow-up survey and clinical practice guidelines:the outstanding achievements of the liver cancer study group of Japan. Dig Dis，2015，33（6）:765-770.
[12] Yang WS，Shu XO，Gao J，et al. Prospective evaluation of type 2 diabetes mellitus on the risk of primary liver cancer in Chinese men and women. Ann Oncol，2013，24（6）:1679-1685.
[13] Zhang H，Nie W，Huang F. The correlation relationship between P14ARF gene DNA methylation and primary liver cancer. Med Sci Monit，2015，21:3077-3082.
[14] Gille H，Hülsmeyer M，Trentmann S，et al. Functional characterization of a VEGF-A-targeting anticalin，prototype of a novel therapeutic human protein class. Angiogenesis，2016，19（1）:79-94.
[15] Luo M，Hou L，Li J，et al. VEGF/NRP-1 axis promotes progression of breast cancer via enhancement of epithelial-mesenchymal transition and activation of NF-κB and β-catenin. Cancer Lett，2016，373（1）:1-11.
[16] Keating GM. Bevacizumab:a review of its use in advanced cancer. Drugs，2014，74（16）:1891-1925.
[17] Behera M，Pillai RN，Owonikoko TK，et al. Bevacizumab in combination with taxane versus non-taxane containing regimens for advanced/metastatic nonsquamous non-small-cell lung cancer:a systematic review. J Thorac Oncol，2015，10（8）:1142-1147.
[18] Soffietti R，Trevisan E，Bertero L，et al. Bevacizumab and fotemustine for recurrent glioblastoma:a phase II study of AINO （Italian association of neuro-oncology. J Neurooncol，2014，116（3）:533-541.
[19] 朱帝文，张海潇，顾俊鹏. 抗VEGF单克隆抗体动脉灌注联合化疗栓塞术治疗原发性肝癌的血管造影变化及初步评价. 中华全科医学，2015，18（3）:350-354.
[20] 刘洪金，赵忠鹏，付艳. 贝伐珠单抗引起肝癌细胞HepG2的VEGF受体2上调表达. 解放军医学院学报，2014，35（5）: 474-488.
[21] 吴荣敏，方晓燕，凌雁武，等. 牵牛子对二乙基亚硝胺诱发大鼠肝癌的抑制作用. 医药导报，2015，34（4）:463-466.